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Exposure to whole cigarette smoke from reference cigarettes results in the prompt (peak activity is 6
hrs), but fairly weak (-2 fold), induction ofmurine pulmonary microsomal monooxygenase activity. This
activity can be detected by using as substrates either benzo(a)pyrene or ethoxyresorufin, and can be
inhibited by treatment with cycloheximide or actinomycin D. Unlike the induction of pulmonary
monooxygenases following intratracheal administration of 3-methylcholanthrene, these cigarette
smoke-induced increases were not unequivocally linked to the Ah locus.
Whole smoke condensate and fractions derived from these condensates can; a) induce pulmonary
monooxygenase activity, b) inhibit benzo(a)pyrene metabolism in vitro, c) be metabolized to forms
mutagenic to Salmonella typhimurium tester strains TA1538 or TA98, d) transform C3H 10T/2 cells in
vitro, and e) enhance the carcinogenicity of benzo(a)pyrene in murine pulmonary tissue. A potentially
important observation is that whereas hepatic tissue is capable of activating whole cigarette smoke
condensate to mutagenic forms in vitro, murine pulmonary tissue does not seem capable of such activa-
tion. Although these pulmonary-derived tissue homogenates have significant AHH activity and can
metabolize Aflatoxin B,, 2-aminofluorene and 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene to mutagenic
forms, these homogenates fail to activate both cigarette smoke condensate and the pro-mutagen, 6-
aminochrysene. These results are discussed with reference to the concept that whole cigarette smoke may
be both a potential "initiator" and "promotor" oflung cancer in mice, and that this latter property may
be the most important in determining cancer risk.
Introduction
Cancer is not randomly distributed among the
human population (1), rather, both environmental
(2) and genetic (3-5) factors strongly influence its
occurrence. Lung cancer is a specific example of a
neoplasia whose occurrence is nonrandomly
distributed. Its incidence is often associated with
cigarette smoking (6), but the actual role that to-
bacco smoke or smoke-related chemicals play in
this association is unclear.
A potential role of tobacco smoke involves in-
teraction with those microsomally-bound mono-
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oxygenases that seem important in determining sus-
ceptibility to chemically-induced cancer in model
animal systems (7, 8). These enzymes are important
because not only do they metabolize many en-
vironmental chemicals, but also naturally occurring
variations in their steady-state levels are genetically
linked with susceptibility to toxicity, mutagenesis,
and carcinogenesis induced by many of the same
chemicals (7, 9-11).
Three basic questions can be addressed con-
cerning the role oftobacco smoke in cancer suscep-
tibility in man: (a) Does tobacco smoke contain
chemicals that interact with the microsomal
monooxygenases? (b) If they do interact, what are
some of the in v,ivto and in vitro effects? (c) Can
certain individuals or tissues within an individual be
at greater risk than others from the effects of
tobacco-related chemicals?
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Chemicals Capable of Interacting
with the Monooxygenase
Systems?
Kinetics of increase of pulmonary AHH levels
in C57BL/6 (B6), DBA/2J (D2), and C3H/fCum (C3)
strains ofmice exposed to IAI cigarettes are shown
in Figure 1. Results suggested that there were rapid
increases in pulmonary AHH activity that peaked
by 6 hr post-exposure, and that these induced en-
zymes remained at this level for at least 24 hr. The
D2 strain was virtually nonresponsive to this smoke
exposure compared with B6 and C3 strains; this re-
sult paralleled that found when a polycyclic aro-
matic hydrocarbon (PAH), 3-methylcholanthrene
(MC), was given intratracheally to the same strains
(see Fig. 1). However, the kinetics of induction of
pulmonary AHH by smoke are different from those
obtained when MC was used as an inducer. The
peak of activity in the smoke induced lungs oc-
curred at 6 hr (vs. 24 hr for MC). Also the half-life of
the smoke-induced enzyme was much longer (-24
hr vs. - 4 hr). Finally, these smoke exposure condi-
tions did not induce the AHH activity in liver,
colon, and kidney (data not shown) whereas MC-
treatment did; moreover, filtered smoke (gas phase)
did not induce enzyme activity in lung, liver, or
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FIGURE 1. Pulmonary response ofC3H/fCum, C57BL/6Cum, and
DBA/2J inbred strains of mice to MC and whole cigarette
smoke. Mice were either treated with 200 ,zg MCA/0.2%
gelatin-saline solution intratracheally (IT) as described previ-
ously (12) and sacrificed at the time periods specified or ex-
posed to four cigarettes from a Walton smoking machine
employing a 2-sec puff, 10%, smoke, 30-sec exposure, and
30-sec purge (13). Mice were given a 2-min rest period before
exposure to the next cigarette and were sacrificed at varying
times after the fourth cigarette. Lungs were excised and fro-
zen at -70°C until assayed. AHH units are expressed as
nmole 3-OH-BP formed/min/g wet weight tissue (12). Aver-
age activity of three animals is given.
kidney tissue (data not shown). Smoke-induced
AHH in the lung was similar to MC-induced AHH,
in that both are capable of O-deethylation of
ethoxyresorufin (Table I): see Burke and Mayer
(15) for data on MC as an inducer. Data with
ethoxyresorufin were particularly interesting be-
cause studies have suggested that this chemical is a
specific substrate for the P-448 (or P,-450) cyto-
chrome (/6). This is the cytochrome that is inti-
mately associated with metabolizing ben-
zo[a]pyrene (BP) and MC to cytotoxic (17-19),
mutagenic (2), DNA-binding (21, 22), and car-
cinogenic (9, 10) forms. Similar to MC-induced
AHH levels, the smoke-induced enzyme levels are
dependent upon in vi4io protein and RNA synthesis
(see Table 1).
Although tobacco smoke induced AHH activity
in the B6 strain preferentially to the D2 strain, the
genetic basis for this difference may not be the same
as that for the difference in AHH activity induced
by MC. Figure 2 shows that, whereas MC given
intratracheally to (B6D2) F1 x D2 progeny induced
pulmonary AHH activity in approximately 50%
(13/29) of the mice (12, 13), no clearcut discrimina-
tion was observed in the smoke-exposed animals.
However, it may be that the inducing capacity of
cigarette smoke for pulmonary tissue isjust too low
to easily evaluate its genetic regulation.
Whole tobacco smoke can be collected by con-
densation with the use of Dry Ice, and this cigarette
smoke condensate (CSC) or fractions derived
therefrom (23) can be evaluated for potential
biological effects. The fractionation scheme and
Table 1. Effect of cycloheximide and actinomycin D on smoke-
induced BC3F, lung AHH and ethoxyresorufin O-deethylase
activity."
AHH O-Deethylase
activity, activity
nmole/min-g nmole/min-g
Treatment tissue" tissue'
Machine controls 0.35 <0.04
Smoke 0.70 0.61
Smoke + saline 0.67 0.83
Smoke + propylene glycol 0.53 0.83
Smoke + cycloheximide, 500,ug/g 0.32 0.14
Smoke + actinomycin D, I ,ug/g 0.42 0.15
" Cycloheximide and actinomycin D were injected in-
traperitoneally (IP) in saline or in propylene glycol respectively,
immediately before exposure to one 2AI cigarette on a Walton
smoking machine. Methods given in legend to Fig. 1. Mice were
sacrificed 6 hr after smoke exposure. Procedures were as de-
scribed by Van Cantfort and Gielen (14).
" AHH units are expressed as nmole 3-OH-BP formed/min/g
wet weight of tissue. Average activity of three animals.
' O-Deethylase units are expressed as nmoles resorufin
formed/min/g wet weight oftissue according to the procedures of
Burke and Mayer (15).
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FIGURE 2. Pulmonary response ofB6D2F, x D2 progeny to (top)
MC and (bottom) whole cigarette smoke. Animals were gen-
erated and housed as described before (12). Inoculation of
MC and smoke exposure was given as described in legend to
Figure 1. AHH activity was determined 24 hr after IT instilla-
tion of MC and 6 hr after exposure to cigarette smoke. Mean
and standard deviation is given for the MC-treated popula-
tions that are representative of the nonresponsive (0.23 +
0.10) and responsive (0.95 + 0.30) populations.
nomenclature were as described by Swain et al.
(26). Table 2 summarizes some of these effects. In-
tratracheal administration ofthe whole CSC and re-
constituted fractions induced a small, but signifi-
cant, increase in pulmonary AHH activity. The
CSC fractions varied in their capacity to induce
AHH activity with the fractions B,a, B,b, NMeOH,
and NNM the best inducers, fractions BE and WA,
weaker inducers, and fractions BU, SA,, SAE and
SAW, actually inhibiting AHH levels in the lungs.
The fractions that induced AHH activity (e.g. B,a or
B,b) contained chemicals that could metabolically
compete with BP in an in vitro assay (see Table 2).
This implies that CSC contains not only chemicals
that induce pulmonary AHH, but also chemicals
that are potential substrates for these enzymes.
What Are Some in Vitro and in
Vivo Effects of Tobacco-Related
Chemicals?
In Vitro Assays
The preceding section showed that tobacco smoke
contains chemicals which interact with the
monooxygenase system. This interaction can be
beneficial if it produces nonbiologically active,
polar metabolites which can be excreted from the
body, or it can be detrimental if it results in inter-
mediates with exceptional biological potency. Table
2 shows that lAI CSC fractions are metabolized by
enzyme fractions from rat liver to forms mutagenic
to tester strains TA1538 (25, 27) of Salmonella
typhimurium, and also by endogenous cellular en-
zymes to forms capable of transforming the C3H
IOT½/2 cells in culture. This table also depicts the
levels of nicotine, phenols, and BP in fractions BE,
WA,, and NNM-the fractions which contain virtu-
Table 2. Effects of fractions of lAl cigarette smoke condensate (CSC) in various model systems.
(X)/BP
Content, to give 505'o
Fractiona mg/cig AHH inducibilityb inhibitionc Mutagenesisd Transformatione
Whole CSC 23.50 1.7 5.0 +++ +
Reconstituted CSC 23.00 1.8 5.2 +++ +
B,a 0.81 3.6 0.8 ++
B,b 0.29 2.5 0.5 ++ +
BE 0.95 1.5 3.0 +
Bw 0.36 0.5 >10.0
WA, 2.27 1.6 5.0 ++ +
WAE 1.98 1.1 2.0 +
SA, 0.39 0.5 >10.0 +
SAE 0.78 0.3 >10.0
SAw 8.69 0.4 >10.0
NMeOH 1.19 2.5 3.0 +
NCH 4.58 1.2 ND -
NNM 0.70 3.2 1.0 + -
a Whole CSC has 21.0 mg nicotine/g, 5.70 mg phenols/g, and 0.98 ug BP/g. Reconstituted CSC has 22.0 mg nicotine/g, 5.5 mg
phenols/g, and 0.90,ug BP/g. BE has 31.0 mg nicotine/g, WAE has 41 mg phenols/g, and NNM has 31.1 ,ug BP/g. Details given by Patel et
al. (23).
b AHH inducibility = effect offractions of IAI CSC fractions on pulmonary AHH activity ofC57BL/6 Cum mice relative to acorn oil
control (12).
c BP inhibition = competitive in vitro effect ofCSC fractions of BP metabolism by hepatic microsomes from 3-methylcholanthrene-
treated C57BL16 mice (13).
d Mutagenesis = mutagenic activity of lAI CSC fractions in Salmonella typhimurium TA 1538 in the presence of liver microsomal
S-9 mix (24).
e Transformation = malignant transformation frequency in C3H lOTl/2 Cl. 8 cells treated with CSC fractions (25).
65 April 1979ally all of these three chemicals. The most biologi-
cally active fractions are not those that contain the
BP or phenols. The B,a and B,b fractions have not
been analyzed fortheirchemical content. However,
because of the nature of the fractionation scheme
(B,a = bases insoluble after ether, B,b = bases in-
soluble before ether), these fractions could contain
some aromatic amine-like chemicals.
A similar distribution of mutagenic activity was
found with CSC fractions from the 2A1 reference
cigarette (Table 3), and such activity was observed
to be stable even ifthe fractions were stored frozen
for one year. Thus, for at least two different types of
cigarettes, certain fractions oftheircondensates can
be metabolized to forms that are active in an in vitro
mutagenesis test system.
However, subsequent studies (Table 4) revealed a
potentially important hindrance to the extrapolation
of the foregoing studies to an in vivo situation.
Mouse pulmonary tissue preparations, under con-
ditions where BP is significantly metabolized to
3-OH-BP (see AHH levels), failed to significantly
activate either 2A1 condensate or 6-aminochrysene
(6-AC) to forms mutagenic to the TA98 tester strain.
Table 3. Mutagenesis of TA 98 with 2A1 cigarette smoke condensate (CSC) fractions.a
Mutants per plate Calculated mutants
per 250 jig of per plate per
Content, sample cigarette Activity, %
Fraction mg/cig Expt 1 Expt 2 Expt I Expt 2 Expt 1 Expt 2
Whole CSC 40.00 133 122 21,280 19,520
Reconstituted CSC 39.50 159 148 25,122 23,284
BIa 0.60 987 1,149 2,369 2,758 11 10
BIB 0.24 3,510 5,266 3,370 5,055 16 18
BE 1.04 1,258 2,065 5,233 8,590 25 30
Bw 0.52 102 151 212 314 1 1
WA, 3.63 289 394 4,1% 5,721 20 20
WAE 2.66 141 206 1,500 2,192 7 8
SA, 1.44 53 43 305 248 2 1
SAe 0.88 8 14 28 49 0 0
SAW 15.60 8 20 499 1,248 2 4
NMeOH 2.16 65 93 562 804 3 3
NCH 9.54 57 24 2,175 916 10 3
NNM 1.24 80 139 397 689 2 2
a The 2AI (low nicotine) CSC fractions were generated by Meloy Laboratories according to the methods ofPatel et al. (23) and the
pour plate incorporation mutagenesis assay was performed according to the methods of Kier et al. (24).
Table 4. Capacity of TCDD-induced mouse hepatic and pulmonary S-9, and Aroclor 1254-induced rat hepatic S-9 to activate whole
cigarette smoke condensate to form(s) mutagenic to S. typhimurium TA 98.a
Compound AHH, Survival, Mutants/plate
Source of S-9 Type ug/plate Protein, mg pmole/tubeb %r (minus background)
C57BL/6 hepatic
Pour plate 2A1 650 3.14 4929 115
AFBI 1 3.14 4929 170
Suspension 2A1 260 3.14 4929 109 61
6-AC 5 3.14 4929 102 115
C57BIJ6 pulmonary
Pour plate 2A1 1300 11.5 8800 8
AFB, 25 11.5 8800 250
Suspension 2A1 1300 1.44d 1071 105 5
6-AC 125 6.90 3208 83 3
Rat hepatic
Pour plate 2A1 1300 4.43 9625 185
AFBI 1 4.43 %25 760
Suspension 2A1 650 2.95 7371 106 83
6-AC 0.5 0.03 190 82 315
a Pour plate incorporation mutagenesis assays were performed according to the method of Kier et al. (24). Suspension assays
consisted of a 35 min incubation of a mixture of bacteria, S-9, and test chemicals in a buffer composed of3.6 mM NADPH, 4.2 mM
NADH, 3 mM MgCl2, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCI and 137 mM NaCI.
b As pmole 3-OH-BP formed per assay tube; total time was 35 min; 25 ,ug BP/ml was substrate.
e Percentage of bacteria surviving 35 min suspension relative to TA 98 alone.
d Subsequent assays with 11.5 mg protein, 8800 units AHH, and 1300 ,g 2A1 still showed no induced mutants.
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patic tissue could activate both 6-AC and the 2A1
CSC to mutagenic intermediates. However, the
pulmonary S-9 preparations were capable of ac-
tivating aflatoxin B1 (AFB,) (see Table 4), 7,8-
dihydro-7,8-dihydroxybenzo(a)-8-diol pyrene-7,
and 2-aminofluorene (2-AF) to mutagenic forms
(Table 5). Thus, the lung preparations were
metabolically active by some measures, but did not
activate 6-AC or CSC. That the tissue hypotheti-
cally at risk to tobacco-associated carcinogenesis
seems unable to activate the tobacco smoke con-
densate allows many interesting interpretations
which will be discussed in the last section of this
report.
In Vivo Studies
Tobacco smoke condensate fractions have been
shown to ""promote" carcinogen-initiated skin
tumors in mice (28, 29). Table 6 demonstrates that
at least some fractions from the 2A1 CSC are capa-
ble of acting synergistically with intratracheally in-
stilled BP (with or without Fe203), resulting in a
much higher incidence of lung cancers in BC3Fl
mice; see Saffiotti (30) for discussion on use of
Fe2O3 in pulmonary cancer model systems. BP
alone (given every other weekfor6 weeks) resulted in
only one malignant tumor by 39 weeks after treat-
ment out of a total of82 treated animals (combining
animals given 0.6 mg and 1.2 mg BP per treatment).
Table 5. Activation of7,8-dihydro-7,8-dihydroxybenzo[a]pyrene (7,8-diol) and 2-aminofluorene (2-AF) by pulmonary S-9."
Pulmonary S-9, 2-AF, 7,8-diol, AHH, Survival, Mutants/
mg protein ,ug/tube ug/tube pmole/tubeb loc plate
6.57 25 1904 48 536
10 1925 81 668
10 1904 61 521
3.28 25 1452 52 458
10 1452 52 540
5 1680 101 627
0 25 82 39
10 84 52
6.57 0.5 1928 57 544
3.28 0.5 1680 18 338
0 1.0 88 76
0 0.1 99 84
TA 98 alone - 100 20
a Suspension assays performed according to procedures given in Table 4.
b AHH = pmoles 3-OH-BP formed per 35 min incubation in separate tubes containing 25 ,ug BP/ml as substrate.
c Percentage of viable bacteria after 35 minute assay relative to TA 98 alone.
Table 6. Evaluation of cocarcinogenic effects of 2A1 CSC and selected fractions of the condensates on BP-initiated
lung cancers in BC3FI mice.a
Gel CSC fractionb
Treatment group salineb B,a B,b WA, NMeOH RF SMd
No other treatment 0/118 0/37 1/47 0/28 1/40 0/68 0/50
0.6 mg Fe2O3 0/48 1/47 0/71 0/48 0/46 2/65 0/51
0.6 mg BP 1/43 10/64 5/74 14/59 19/82 4/60 13/58
1.2 mg BP 0/39 9/62 3/35 12/46 34/79 10/58 9/66
0.6 mg BP + mg Fe203 3/60 7/64 4/40 2/40 3/50 3/42 1/56
1.2 mg BP + 0.6 mg Fe203 7/69 9/71 13/57 6/55 10/74 5/47 11/50
a Groups ofBC3F,/Cum female mice(8-14 weeks old) were intratracheally (IT) inoculated once every 2 weeks for a total of6 weeks
with 0.02 ml gelatin-saline solutions of BP, Fe.O3, BP:Fe203 alone or in combinations with the cigarette smoke condensate (CSC)
fractions (10 ,ug each). At the end of the "carcinogen treatment" period, IT treatment with the appropriate CSC fractions was
continued once every 2 weeks until 4 weeks priorto sacrifice. Datapresented represents tumor incidence for mice randomly sacrificed
after 26 and 39 weeks on test. The tumor types diagnosed histopathologically include alveologenic adenocarcinomas, adenosquamous
carcinomas, squamous cell carcinomas, and squamous neoplasms. A more complete description of these lung cancers is given
elsewhere (33).
b Data given in terms of the number of mice with lung carcinomas per the total number of animals at risk.
c RF = reconstituted fractions.
d SM = starting material.
April 1979 67Addition offerric oxide (Fe203) with BP resulted in
8% malignant tumors (30). However, treatment with
selected 2A1 condensate fractions every other week
for the duration ofthe study (39 weeks), resulted in
significantly increased malignant lung lesions in
animals treated with both BP alone or with BP plus
Fe203. The fractions alone, or with Fe203, resulted
in few malignant tumors (5 out of a total of 764
treated animals). Thus, in an in vivo lung tumor
model system, the fractions seemed to have mainly
"'promotor-like" activity.
Can Individuals or Tissues within
an Individual Differ in Risk to the
Effects of Tobacco-Related
Chemicals?
The answers to this question are at best complex.
The results ofstudies discussed in the previous sec-
tions can be somewhat difficult to reconcile. On the
one hand, tobacco smoke contains chemicals that
interact with hepatic mixed-function oxidases such
as AHH, and this metabolism generates inter-
mediates that are mutagenic and transforming in in
vitro test systems. On the other hand, CSC is not
activated to mutagenic forms by mouse-derived
pulmonary tissues in vitro. Also, CSC material does
not seem to efficiently cause lung tumors in vivo.
Many interpretations are feasible. Perhaps the lack
of activation is characteristic of mouse pulmonary
tissue alone and cannot be generalized to other
species. In point of fact, rat pulmonary tissue has
been reported to activate certain smoke conden-
sates to mutagenic forms (24). However, both rat
and human lung tissues have also failed to activate
CSC material (24, 31), and so the generality of the
activation (or lack thereof) is still not understood.
Second, the fact that hepatic tissue can activate
these condensates suggests that tobacco material
could be activated by this organ and, following that,
the tissues at risk (e.g., lung) would be exposed to
these active forms. Or third, the lung is at risk only
for the effects ofthose chemicals in cigarette smoke
capable of"promoting" the carcinogenic event that
may be initiated by a myriad of environmental pol-
lutants.
The first interpretation is difficult to assess be-
cause no lung cancer model animal system directly
applicable to man is currently available. However,
the kind of pulmonary lesions observed in mice fol-
lowing exposure to known chemical carcinogens,
that is, bronchogenic squamous cell carcinomas, al-
veolar adenocarcinomas, and adenosquamous car-
cinomas, resemble lesions found in man (32, 33).
Some data suggest that the liver plays a major
role in the eventual susceptibility ofother organs to
chemically-induced cancers (34). However, no evi-
dence is available to suggest that lung tissue is at
risk from liver-metabolized chemicals. Evaluation
ofthis alternative in vivo will be difficult because of
the close liver/lung relationship.
The third interpretation is particularly intriguing
and suggests that ""promotion" represents the real
risk of cigarette smoke to lung tissue. This idea is
consistent with the following facts: (a) tobacco
smoke condensate is capable of "promoting"
mouse skin carcinogenesis; (b) tobacco-smoke con-
densate can "promote" lung carcinogenesis in
model animal systems (see Table 6); (c) the condi-
tions of cigarette-smoke exposure that result in the
highest risk of human lung cancer are quite similar
to those that are most promotive in animal test sys-
tems; that is, frequent and relatively prolonged
treatment; (d) the chemicals in cigarette smoke
(particulate phase) that are known initiators of car-
cinogenesis may be too low in concentration [total
= 400 ng/cigarette (35)] to initiate significant trans-
formation in vivo. The evaluation ofwhole cigarette
smoke as a potential initiator and promoter of lung
cancer in the inbred strains of mice is now being
studied in our laboratory.
NOTE ADDED IN PROOF: We have recently found
that a pulmonary S-9 preparation from Aroclor
1254-induced mice is capable of weakly activating
6-AC to a bacterial mutagen with the use of a pour
plate assay (2-3-fold over background). We have still
not observed an increase in bacterial mutations using
this S-9 preparation and 2AI cigarette smoke con-
densate.
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